On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia.
The effectiveness of orally administered iron was investigated using three different iron preparations in a randomized study with 3 patient groups, each consisting of 20 subjects with iron deficiency anaemia. Group A received a ferric(III)-dextrin complex, group B Fe(II)-sulfate, and group C Fe(II)-fumarate with vitamins. For all three preparations the increase in the number of erythrocytes as well as hemoglobin and hematocrit values ran absolutely parallel for a period of 12 weeks. A relevant difference between the trivalent ferric-dextrin complex and the two bivalent iron preparations could not be detected on evaluation of the parameters measured except for a moderate increase in the transaminase values in the patients group who received the Fe(II)-sulfate preparation. No differences were found among the preparations with respect to tolerance. The results are discussed with respect to a possible overloading of the iron transport system by highly absorptive Fe(II)-preparations.
D000328:Adult; D000747:Anemia, Hypochromic / Q000097:blood / Q000188:drug therapy*; D004906:Erythrocyte Count; D005260:Female; D005290:Ferric Compounds / Q000097:blood / Q000627:therapeutic use*; D005296:Ferrous Compounds / Q000097:blood / Q000627:therapeutic use*; D005492:Folic Acid / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D014805:Vitamin B 12 / Q000627:therapeutic use
D005290:Ferric Compounds; D005296:Ferrous Compounds; D006454:Hemoglobins; C021024:ferric hydroxide; C024823:ferric sulfate; D005492:Folic Acid; D007501:Iron; D007770:L-Lactate Dehydrogenase; D014805:Vitamin B 12; C031621:ferrous fumarate